Entod Pharma extends business

Entod Pharmaceuticals on Monday announced the opening of GLO division, an ocular subspeciality division focusing on the treatment of glaucoma, a major contributor to permanent blindness in India. This move was made in an effort to grow the company.

The #TheGLOProject is a national public awareness campaign that Entod Pharmaceuticals has been implementing. To spread awareness of the eye ailment, the pharmaceutical industry has partnered with the World Glaucoma Association and other national and regional glaucoma medical associations.

Entod Pharmaceuticals has been running a national public awareness campaign called #TheGLOProject. The pharmaceutical sector has joined up with the World Glaucoma Association and other national and regional glaucoma medical associations to raise awareness of the eye condition.

Entod Pharma

For our company, this year has been both difficult and spectacular because we concentrated on broadening our horizons outside the convention. The most recent achievement, the opening of our GLO Division, is intended to bring about significant improvements in the glaucoma situation in our nation, according to Nikkhil K. Masurkar, CEO of Entod Pharmaceuticals.

Through this division, more than 95% of anti-glaucoma compounds and treatments that are now available globally will be covered, providing access to millions of patients nationwide. Additionally, our research teams are actively looking at a number of novel glaucoma therapy approaches that will offer the most recent advancements in treatment. Entod Pharmaceuticals offers approximately 270 treatment options that address ENT, dermatology, and all significant eye health disorders.